Literature DB >> 28864555

Distinct Signaling Patterns of Allosteric Antagonism at the P2Y1 Receptor.

Zhan-Guo Gao1, Kenneth A Jacobson1.   

Abstract

Traditionally, G protein-coupled receptor antagonists are classified as competitive or noncompetitive and surmountable or insurmountable based on functional antagonism. P2Y1 receptor (P2Y1R) structures showed two antagonists binding to two spatially distinct sites: nucleotide MRS2500 (orthosteric, contacting the helical bundle) and urea BPTU (allosteric, on the external receptor surface). However, the nature of their P2Y1R antagonism has not been characterized. Here we characterized BPTU antagonism at various signaling pathways activated by structurally diverse agonists. BPTU rightward shifted the concentration-response curves of both 2-methylthioadenosine 5'-diphosphate trisodium salt and MRS2365 (5'-diphosphates) in some signaling events, such as extracellular signal-regulated kinase 1/2 and label free, in a parallel manner without affecting the maximum agonist effect (Emax) but antagonized insurmountably (suppressed agonist Emax) in signaling events such as guanosine 5'-3-O-(thio)triphosphate binding and β-arrestin2 recruitment. However, with dinucleotide Ap4A as an agonist, BPTU suppressed the Emax insurmountably in all signaling pathways. By comparison, MRS2500 behaved as surmountable antagonist rightward-shifting concentration-response curves of all three agonists in a parallel manner for all signaling pathways measured. Thus, we demonstrated a previously undocumented phenomenon that P2Y1R antagonism patterns could vary in different signaling pathways, which could be related to conformational selection, signaling amplification, and probe dependence. This phenomenon may apply generally to other receptors considering that antagonism by a specific ligand is often not compared at multiple signaling pathways. Thus, antagonism can be surmountable or insurmountable depending on the signaling pathways measured and the agonists used, which should be of broad relevance to drug discovery and disease treatment. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28864555      PMCID: PMC5635520          DOI: 10.1124/mol.117.109660

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  43 in total

Review 1.  Drug-target residence time--a case for G protein-coupled receptors.

Authors:  Dong Guo; Julia M Hillger; Adriaan P IJzerman; Laura H Heitman
Journal:  Med Res Rev       Date:  2014-02-18       Impact factor: 12.944

2.  Agonist action of adenosine triphosphates at the human P2Y1 receptor.

Authors:  R K Palmer; J L Boyer; J B Schachter; R A Nicholas; T K Harden
Journal:  Mol Pharmacol       Date:  1998-12       Impact factor: 4.436

3.  Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers.

Authors:  Zhan-Guo Gao; Dennis Verzijl; Annelien Zweemer; Kai Ye; Anikó Göblyös; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2011-06-21       Impact factor: 5.858

4.  What is pharmacological 'affinity'? Relevance to biased agonism and antagonism.

Authors:  Terry Kenakin
Journal:  Trends Pharmacol Sci       Date:  2014-07-17       Impact factor: 14.819

5.  beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.

Authors:  Sudha K Shenoy; Matthew T Drake; Christopher D Nelson; Daniel A Houtz; Kunhong Xiao; Srinivasan Madabushi; Eric Reiter; Richard T Premont; Olivier Lichtarge; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2005-11-09       Impact factor: 5.157

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis.

Authors:  Ryan T Kendall; Mi-Hye Lee; Dorea L Pleasant; Katherine Robinson; Dhandapani Kuppuswamy; Paul J McDermott; Louis M Luttrell
Journal:  J Biol Chem       Date:  2014-07-31       Impact factor: 5.157

8.  Translocation of arrestin induced by human A(3) adenosine receptor ligands in an engineered cell line: comparison with G protein-dependent pathways.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Pharmacol Res       Date:  2008-03-08       Impact factor: 7.658

9.  Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors.

Authors:  Mounia Azzi; Pascale G Charest; Stéphane Angers; Guy Rousseau; Trudy Kohout; Michel Bouvier; Graciela Piñeyro
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-17       Impact factor: 11.205

Review 10.  Taking the time to study competitive antagonism.

Authors:  D J A Wyllie; P E Chen
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

View more
  10 in total

1.  Characterisation of P2Y2 receptors in human vascular endothelial cells using AR-C118925XX, a competitive and selective P2Y2 antagonist.

Authors:  Markie O Muoboghare; Robert M Drummond; Charles Kennedy
Journal:  Br J Pharmacol       Date:  2019-07-06       Impact factor: 8.739

2.  Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors.

Authors:  Barbara Cacciari; Pamela Crepaldi; Chun Yan Cheng; Elena Bossi; Giampiero Spalluto; Stephanie Federico; Kenneth A Jacobson; Marco Cattaneo
Journal:  Med Chem       Date:  2019       Impact factor: 2.745

3.  Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses.

Authors:  Antonella Ciancetta; Robert D O'Connor; Silvia Paoletta; Kenneth A Jacobson
Journal:  J Chem Inf Model       Date:  2017-11-28       Impact factor: 4.956

Review 4.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

5.  Characterization of the antagonist actions of 5-BDBD at the rat P2X4 receptor.

Authors:  Claudio Coddou; Rodrigo Sandoval; María José Hevia; Stanko S Stojilkovic
Journal:  Neurosci Lett       Date:  2018-10-23       Impact factor: 3.046

6.  Structure activity relationship of 3-nitro-2-(trifluoromethyl)-2H-chromene derivatives as P2Y6 receptor antagonists.

Authors:  Young-Hwan Jung; Shanu Jain; Varun Gopinatth; Ngan B Phung; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2021-04-06       Impact factor: 2.940

Review 7.  Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  ChemMedChem       Date:  2020-09-18       Impact factor: 3.540

Review 8.  Update of P2Y receptor pharmacology: IUPHAR Review 27.

Authors:  Kenneth A Jacobson; Esmerilda G Delicado; Christian Gachet; Charles Kennedy; Ivar von Kügelgen; Beibei Li; M Teresa Miras-Portugal; Ivana Novak; Torsten Schöneberg; Raquel Perez-Sen; Doreen Thor; Beili Wu; Zhenlin Yang; Christa E Müller
Journal:  Br J Pharmacol       Date:  2020-04-06       Impact factor: 9.473

9.  Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y1 and P2Y12 receptors.

Authors:  Xuyang Liu; Zhan-Guo Gao; Yiran Wu; Raymond C Stevens; Kenneth A Jacobson; Suwen Zhao
Journal:  Sci Rep       Date:  2018-05-24       Impact factor: 4.379

10.  Allosteric Antagonism of the A2A Adenosine Receptor by a Series of Bitopic Ligands.

Authors:  Zhan-Guo Gao; Kiran S Toti; Ryan Campbell; R Rama Suresh; Huijun Yang; Kenneth A Jacobson
Journal:  Cells       Date:  2020-05-12       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.